VanEck Biotech ETF

Juniper Therapeutics CEO Martin Rosenthal Sells 9,500 Shares for $5.34 Million

Gilead Issues $3 Billion Senior Notes for General Corporate Purposes

Quinn Emanuel Fined $3M and Mandated Training for Misleading Court in Natera Case

United Therapeutics CFO James Edmonds Sells $5.64M in Stock

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

Pinned News

置顶新闻

BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary

PHGE

DFNS

SBIO

LABU

IBBQ

BiomX Inc. reported a net loss of $19.14M for Q1 2026, up from $7.66M in Q1 2025, as it shifts focus from biopharma to defense technology. The company acquired Zorronet and a 60% stake in DFSL, launching a new unit, X Security. Revenue contributions from these acquisitions are expected starting Q2 2026, with active projects underway with major clients.

TradingView

T3 Defense

SPDR S&P Biotech

iShares Biotechnology ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Elbit

INBX

Transcenta reported positive interim results from partner Inhibrx’s trial of ozekibart for advanced colorectal cancer, showing a 20% overall response rate and manageable side effects. Inhibrx has also filed for U.S. approval of ozekibart for chondrosarcoma. Transcenta is reviewing its regional plans following these developments and Inhibrx plans to meet the FDA in late 2026 to discuss further trials.

PUBT

Inhibrx Biosciences

TRANSCENTA-B

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Transcenta partner Inhibrx reports 20% ORR in ozekibart colorectal cancer trial

NBTX

ARKG

Nanobiotix reported promising early safety and activity signals from its Phase 2 CONVERGE study in stage 3 unresectable non-small cell lung cancer, showing an 85.7% overall response rate (ORR). Most patients experienced tumor shrinkage, with several achieving complete responses. The trial, sponsored by Johnson & Johnson, supports the feasibility of intratumoral administration without new safety concerns.

Nanobiotix SA

Ark Genomic Revolution ETF

Johnson & Johnson

Nanobiotix reports 85.7% ORR in phase 2 CONVERGE lung cancer safety lead-in data

Neurothera Labs Inc. has adopted a semi-annual financial reporting framework effective immediately, under the CBO 51-933 exemption. This change allows the company to avoid filing interim reports for the first and third quarters, reducing administrative burdens. Neurothera will continue to file annual audited financial statements and six-month interim reports. The company confirms it meets eligibility criteria, including annual revenues under $10 million.

TheNewswire

Proshares UltraShort Nasdaq Biotech

VG Health

iShares Global Healthcare

Health Care Select Sector SPDR

SciSparc

Neurothera Labs Announces Adoption of Semi-Annual Reporting

JAGX

Jaguar Health reported a Q1 profit of $8.72 million, reversing a loss from the previous year, with revenue soaring 815.6% to $20.27 million. License revenue reached $19.04 million, while product revenue fell 44.5% to $1.2 million. Operating expenses decreased by 13.3% to $10.09 million. The quarter included a licensing deal with Woodward Specialty, providing $16 million upfront. Cash stood at $7.3 million as of March 31, 2026, though concerns about ongoing viability remain.

Jaguar Health

Jaguar Health turns to Q1 profit; revenue more than doubled to $20.27 million

RLAY

Relay Therapeutics' drug zovegalisib shows promise in treating vascular anomalies, achieving a 60% response rate in a mid-stage trial. Most patients reported symptom improvement, and the drug appears safe for chronic use. Relay's shares rose by 10% following the announcement. Analysts predict zovegalisib could generate $2.8 billion in peak annual sales, highlighting its potential as a leading treatment in this area. Further testing is planned, with results expected by year-end.

biopharmadive

Relay Therapeutics

NOVARTIS AG

Novartis AG

Relay drug shows early promise against rare blood vessel diseases

CRVS

Corvus Pharmaceuticals CEO Richard A. Miller purchased 6,932 shares of common stock through a family trust for a total of USD 83,112, at prices of USD 12.05 and USD 12.01 per share. The trust's total holdings increased to 1,195,035 shares after the transaction.

Corvus Pharma

Corvus CEO Richard Miller reports trust buy of USD 83,112 common shares

ELIL

LLYX

Engage Biologics Inc. has been acquired by Eli Lilly and Company for up to $202 million to enhance the development of non-viral genetic medicines. Engage's Tethosome platform aims to improve DNA delivery's potency, tolerability, and redosability. The acquisition combines Engage's innovative technology with Lilly's extensive genetic medicine capabilities, promising to accelerate the development of new genetic therapies.

Fidelity

Eli Lilly

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

KRRO

Korro Bio Inc. has chosen KRRO-111 as a candidate for clinical development to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting 3.4 million people globally. KRRO-111, a GaINAc-conjugate oligonucleotide, has shown over 90% RNA-editing success in preclinical studies. The company plans to present data on its preclinical validation. KRRO shares are currently trading at $9.32, up 1.86%.

nasdaq

Korro Bio

Nasdaq

Korro Bio To Advance KRRO-111 As Potential Treatment For AATD

IBRX

ImmunityBio's stock surged 9% following the FDA's acceptance of its supplemental biologics license application for Anktiva, which could expand its use in treating bladder cancer. This approval could significantly increase the patient base, supporting the company's strong sales growth. However, with the stock already quadrupling this year, investors are advised to approach cautiously. The FDA's target action date is set for January 6, 2027.

ImmunityBio

NVIDIA

Intel

Netflix

S&P 500

NVIDIA Corporation

Why ImmunityBio Stock is Soaring Higher Today

Guardant Health announced that the US FDA has approved its Guardant360 Liquid CDx, a liquid biopsy test for non-small cell lung cancer and colorectal cancer. This test offers enhanced genomic profiling from a single blood draw and can detect circulating tumor DNA with greater sensitivity. It assesses a 100-times wider genomic footprint than its predecessor and delivers results within seven days. Following the announcement, shares rose over 5% in premarket trading.

Guardant Health

iShares Genomics Immunology and Healthcare ETF

Guardant Health Says US FDA Approved Liquid Biopsy Test

Bristol Myers Squibb (BMY) is partnering with Anthropic to implement its Claude AI model for over 30,000 employees, aiming to enhance drug discovery and development processes. The initiative includes using Claude Code for various functions, moving beyond simple chatbot applications. BMY shares rose 1.74% to close at $58.31.

Tip Ranks

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

Bristol-Myers Squibb Company

BMY Stock Rises as Bristol Myers Brings Anthropic's Claude AI to 30,000 Employees

VanEck Biotech ETF(BBH.US)